Delving into the Latest Updates on Tenofovir disoproxil phosphate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

tenofovir disoproxil, Tefovir

Target

RT

Action

inhibitors

Mechanism

RT inhibitors(Viral reverse transcriptase inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesDigestive System Disorders+ [1]

Active Indication

Hepatitis BHepatitis B, ChronicHIV Infections

Inactive Indication-

Originator Organization

Hanmi Pharmaceutical Co., Ltd.

Active Organization

Viatris Ltd. (New Zealand)Lupin Australia Pty Ltd.

Hanmi Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

European Union (08 Dec 2016),

Hepatitis B, ChronicHepatitis BHIV Infections

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC19H33N5O14P2

InChIKeyDJCLNKKHALBVLK-PFEQFJNWSA-N

CAS Registry1453166-76-1

View All Structures (2)

The purpose of this study is to evaluate the efficacy in terms of hepatitis B surface antigen (HBsAg) changes from baseline for the treatment regimens of 24 weeks of JNJ-73763989 + 24 weeks of nucleos(t)ide analog (NA) + 12 or 24 weeks of pegylated interferon alpha-2a (PegIFN-alpha-2a) (with immediate or delayed start of PegIFN-alpha-2a treatment).

Start Date03 Nov 2021

Sponsor / Collaborator

Janssen Research & Development LLC

NCT04667104

/ CompletedPhase 2

A Phase 2, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection

The purpose of this study is to evaluate the efficacy in terms of hepatitis B surface antigen (HBsAg) levels of the study intervention (that is, JNJ-73763989 + JNJ-56136379 + nucleos[t]ide analog [NA] and pegylated interferon alpha-2a [PegIFN-alpha2a]).

Start Date01 Feb 2021

Sponsor / Collaborator

Janssen Research & Development LLC

NCT04453436

/ Unknown statusNot Applicable

HIV Drug Resistance Profiles Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil

Brazil was the first middle-income country to provide free and universal access to antiretroviral drugs to HIV infected individuals. Since 2014 local guidelines recommend that all HIV infected individuals be started on therapy regardless of CD4 count. Since January 2017, all patients are started on a DTG containing triple regimen. As of November 2018, 170,000 individuals were receiving DTG through the public health system. It is a public health priority to evaluate the risk of virologic failure and the subsequent development of INSTI resistance in these real-life settings. Our preliminary data from Brazil indicated a high virologic failure rate of 8% after 18 months of treatment TL+D. Our central hypothesis is that TDR may be associated and contribute to virologic failure with DTG in clinical practice. To test this central hypothesis, we will identify PLWH failing DTG containing regimens in Brazil. The insights generated with these studies will contribute to a more effective use of second generation INSTI in the future.

Start Date01 Sep 2020

Sponsor / Collaborator

Universidade Federal De Sao Paulo

[+1]

100 Clinical Results associated with Tenofovir disoproxil phosphate

Login to view more data

100 Translational Medicine associated with Tenofovir disoproxil phosphate

Login to view more data

100 Patents (Medical) associated with Tenofovir disoproxil phosphate

Login to view more data

253

Literatures (Medical) associated with Tenofovir disoproxil phosphate

01 Dec 2024·European Journal of Medicinal Chemistry

Sensitive quantification of fibroblast activation protein and high-throughput screening for inhibition by FDA-approved compounds

Article

Author: Šácha, Pavel ; Šimková, Adéla ; Konvalinka, Jan ; Staňurová, Jana ; Wichterle, Filip ; Čermáková, Kateřina ; Bušek, Petr ; Kryštůfek, Robin ; Vaníčková, Zdislava

Fibroblast activation protein (FAP) has been extensively studied as a cancer biomarker for decades. Recently, small-molecule FAP inhibitors have been widely adopted as a targeting moiety of experimental theranostic radiotracers. Here we present a fast qPCR-based analytical method allowing FAP inhibition screening in a high-throughput regime. To identify clinically relevant compounds that might interfere with FAP-targeted approaches, we focused on a library of FDA-approved drugs. Using the DNA-linked Inhibitor Antibody Assay (DIANA), we tested a library of 2667 compounds within just a few hours and identified numerous FDA-approved drugs as novel FAP inhibitors. Among these, prodrugs of cephalosporin antibiotics and reverse transcriptase inhibitors, along with one elastase inhibitor, were the most potent FAP inhibitors in our dataset. In addition, by employing FAP DIANA in the quantification mode, we were able to determine FAP concentrations in human plasma samples. Together, our work expands the repertoire of FAP inhibitors, analyzes the potential interference of co-administered drugs with FAP-targeting strategies, and presents a sensitive and low-consumption ELISA alternative for FAP quantification with a detection limit of 50 pg/ml.

01 Sep 2024·International Journal of STD & AIDS

Acute hepatitis B in a hepatitis B vaccine non-responder

Article

Author: Cherif, Soumeya ; Seneviratne, Kanch ; Scott, Jane

Developing acute hepatitis B in immunocompetent non-responders to hepatitis B vaccination has been rarely reported. We report such a case in a 79 year old heterosexual male. There is evidence that tenofovir disoproxil/emtricitabine as primary prophylaxis can prevent acquisition of hepatitis B. In the current era of HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil/emtricitabine, there is dual benefit of preventing HIV and hepatitis B. We discuss the importance of considering tenofovir disoproxil/emtricitabine pre-exposure prophylaxis in those hepatitis B vaccination non-responders at high risk of acquiring hepatitis B.

01 Sep 2024·Journal of Hepatology

Association between antiviral treatments and fracture in elderly patients with HBV needs further evaluation

Letter

Author: Jiang, Zai-Bo ; Wu, Jia-Lin ; Luo, Jun-Yang

This article is about long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B which was published in a recent issue of the Journal of Hepatol.This topic is particularly intriguing as it explores the impact of entecavir (ETV) and tenofovir disoproxil (TDF) on the risk of bone fracture in patients with chronic hepatitis B based on a real-world territory-wide cohort.Their findings revealed that long-term TDF treatment for 2 years or more is associated with a higher incidence of bone fracture in older patients.Although this study was elegantly designed and inspiring, we believe that certain aspects warrant further discussion.Addnl., individuals with osteosarcopenia are significantly more likely to experience falls, fractures, and mortality than in non-osteosarcopenic groups.Therefore, this information is imperative for the readers knowledge, and baseline variables which should include bone mineral d. and sarcopenia index prior to the antiviral treatments are needed to draw a robust conclusion.Secondly, they noted that TDF-treated patients with a match were older and more likely to be female, as per the propensity score-matching.Here authors discovered that patients receiving TDF had a higher risk of developing incident fractures compared to those treated with ETV after 24 mo (weighted subdistribution hazard ratio 2.33, 95% CI 1.20 - 4.55, p = 0.014 for age > 65 years; weighted subdistribution hazard ratio 2.12, 95% CI 1.01 - 4.46, p = 0.047 for age > 70 years).Similarly, age and sex could both be risk factors for osteoporosis and fracture, which occur as part of the natural aging process, particularly in relation to menopause and the alterations in sex hormones that accompany advancing age.In order to further validate whether long-term use of TDF increases the risk of fractures in elderly patients with chronic hepatitis B, it is advisable to ensure consistency in terms of phys. activity intensity and diet composition between the two groups.In conclusion, while acknowledging the aforementioned points that merit careful consideration, we are genuinely grateful for the contribution of Yip et al. in their work, and their fi ndings support the current treatment guidelines, advocating for the customization of antiviral therapy based on age and comorbidities.

100 Deals associated with Tenofovir disoproxil phosphate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10834	-	J05AF07	DB00300

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hepatitis B	Liechtenstein	Viatris Ltd. (New Zealand)	08 Dec 2016
Hepatitis B	Iceland	Viatris Ltd. (New Zealand)	08 Dec 2016
Hepatitis B	European Union	Viatris Ltd. (New Zealand)	08 Dec 2016
Hepatitis B	Norway	Viatris Ltd. (New Zealand)	08 Dec 2016
Hepatitis B, Chronic	Iceland	Viatris Ltd. (New Zealand)	08 Dec 2016
Hepatitis B, Chronic	Liechtenstein	Viatris Ltd. (New Zealand)	08 Dec 2016
Hepatitis B, Chronic	European Union	Viatris Ltd. (New Zealand)	08 Dec 2016
Hepatitis B, Chronic	Norway	Viatris Ltd. (New Zealand)	08 Dec 2016
HIV Infections	European Union	Viatris Ltd. (New Zealand)	08 Dec 2016
HIV Infections	Norway	Viatris Ltd. (New Zealand)	08 Dec 2016
HIV Infections	Liechtenstein	Viatris Ltd. (New Zealand)	08 Dec 2016
HIV Infections	Iceland	Viatris Ltd. (New Zealand)	08 Dec 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AASLD2023	Not Applicable	Hepatocellular Carcinoma	3,384	Tenofovir disoproxil (TDF)	(yadfuphuxf) = rtqnfaknmj ncrewmidio (kyatiyyzwc ) View more	-	10 Nov 2023
				Entecavir (ETV)	(yadfuphuxf) = meqfpblldd ncrewmidio (kyatiyyzwc ) View more
ARIA study (IAS2020)	Not Applicable	-	495	DTG/ABC/3TC	(ewcfjvkeqn) = xhbqvxktzk dtscrjzvbc (mvwfmjlhvl ) View more	-	01 Jan 2020
				Atazanavir/ritonavir + tenofovir disoproxil + emtricitabine	(ewcfjvkeqn) = wwzdpjfujk dtscrjzvbc (mvwfmjlhvl ) View more
NCT02577029 (MONARCH, CTgov)	Phase 2	Hepatitis B, Chronic \| Hepatitis D	79	antihistamine+ARC-520 (Cohort 1)	kmlmtbuaaa(mcdodtuotd) = ljqcaavulw jctpdggomy (vfvoeehtwn, mytnagfygp - euddusuorb) View more	-	12 Apr 2019
				antihistamine+tenofovir disoproxil+ARC-520+pegylated interferon alpha 2a+entecavir (Cohort 2)	kmlmtbuaaa(mcdodtuotd) = nshxpyildc jctpdggomy (vfvoeehtwn, blhhkpazxv - bozxzyzoho) View more
NCT00734344 (CTgov)	Not Applicable	HIV Infections	18	Tenofovir disoproxil twice daily+Emtricitibine+Raltegravir (Arm 1)	fowyemakpk(unlyrroofm) = esjlwvfsze itxketmmlb (nuxnpocptu, hxyrcmowwa - uexuxhjgoe) View more	-	30 May 2016
				Tenofovir disoproxil once daily+Emtricitibine+Efavirenz (Arm 2)	fowyemakpk(unlyrroofm) = pgdfpdrvel itxketmmlb (nuxnpocptu, lhipmstpit - ytumwznjyg) View more
Pubmed \| Anesthesiology	Not Applicable	Obstetric Labor, Premature	-	Oral Elixir	erjdoydppq(ovwowkbmpf) = These regimens may cause hepatotoxicity in some individuals if used for longer than 2-3 days bkrqzsdems (ssmwgameoy )	-	01 Jun 2002
				Rectal Solution